'American Drug War II: Cannabis Destiny' is IMDB's Highest Rated 2013 Documentary
COLORADO SPRINGS, Colo., July 8, 2013 /PRNewswire/ -- The X-Change Corporation (NASDAQ OTC: XCHC), a U.S. Company specializing primarily in cannabinoid formulation-based health and wellness solutions, is proud to announce that "American Drug War II: Cannabis Destiny" rated as the highest of all 2013 documentaries with a score of 9.7 out of 10.
The film focuses on the failed U.S. drug war and its affect on a new generation of children. As IMDB states, "Director Kevin Booth navigates through the cutting edge of Cannabis research while becoming a foster parent to a child court ordered to take powerful mind altering drugs."
CFO and SR VP of Business Development of X-Change Corp, Robert Kane, stated, "It has been one of the greatest professional experiences of my life to work with Kevin Booth and his team. It is a privilege to be part of the project from the inception of the business plan, through production and release. To have it #1 on this year's IMDB highest rated documentary list is telling of the quality of production and the power of the film's message. This is important because the story speaks to our country's failed drug policy within a context of inhumane effects on children in need of treatment. We are thankful that the documentary includes the poignant story of little Cash Hyde. The interest in this film is a game changing moment for both the film and entertainment industry as well as the Cannabis industry as the film's success establishes that the market is primed for further investment from media and entertainment giants to support, fund, and invest in related projects."
The film is available on DirecTV Video on Demand. It is also available on iTunes: https://itunes.apple.com/us/movie/american-drug-war-2-cannabis/id635644281?ls=1. In addition, it is available as a Video on Demand from Amazon: http://www.amazon.com/American-Drug-War-Cannabis-Destiny/dp/B00CO0LPWG/ref=sr_1_20?s=instant-video&ie=UTF8&qid=1370536759&sr=1-20.
About The X-Change Corporation
The X-Change Corporation is currently developing new natural cannabinoid containing products based on innovative formulations to utilize the unique and potent benefits of the hemp plant. Medicinal properties of hemp have been known and applied for thousands of years. With the aid of scientific research The X-Change Corporation is translating such knowledge into development of effective cosmeceutical, nutraceutical, and food brands throughout the world. The Company's cosmetics and nutritional lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CFO, Sr Vp of Business Development
SOURCE X-Change Corporation
More by this Source
XCHC Changes Corporate Name to "Endocan Corporation"; Medical Cannabis Industry-Driven Branding Campaign Begins with Name Change and Continues into the Arizona Dispensary Opening
Sep 26, 2013, 09:18 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.